Compare Stocks: BCRX, ABVX, KYMR, and PRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$113.67 +1.7%	$124.95	$69.81 ▼ $148.83	$9.75B	0.97	842,784 shs	991,177 shs
BCRX BioCryst Pharmaceuticals	$9.92 +2.3%	$9.74	$6.00 ▼ $11.22	$2.48B	0.57	3.24 million shs	3.36 million shs
KYMR Kymera Therapeutics	$119.05 +0.2%	$113.58	$39.84 ▼ $130.05	$9.88B	1.96	687,543 shs	576,625 shs
PRAX Praxis Precision Medicines	$353.44 +0.9%	$336.93	$37.19 ▼ $392.70	$9.78B	2.76	432,088 shs	305,830 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+1.74%	-3.61%	-9.01%	+26.09%	+40.28%
BCRX BioCryst Pharmaceuticals	+2.27%	+0.92%	+10.47%	+20.24%	+19.37%
KYMR Kymera Therapeutics	+0.20%	-5.99%	+15.14%	+62.68%	+188.96%
PRAX Praxis Precision Medicines	+0.90%	-3.96%	+14.82%	+26.71%	+676.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$113.67 +1.7%	$124.95	$69.81 ▼ $148.83	$9.75B	0.97	842,784 shs	991,177 shs
BCRX BioCryst Pharmaceuticals	$9.92 +2.3%	$9.74	$6.00 ▼ $11.22	$2.48B	0.57	3.24 million shs	3.36 million shs
KYMR Kymera Therapeutics	$119.05 +0.2%	$113.58	$39.84 ▼ $130.05	$9.88B	1.96	687,543 shs	576,625 shs
PRAX Praxis Precision Medicines	$353.44 +0.9%	$336.93	$37.19 ▼ $392.70	$9.78B	2.76	432,088 shs	305,830 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	+1.74%	-3.61%	-9.01%	+26.09%	+40.28%
BCRX BioCryst Pharmaceuticals	+2.27%	+0.92%	+10.47%	+20.24%	+19.37%
KYMR Kymera Therapeutics	+0.20%	-5.99%	+15.14%	+62.68%	+188.96%
PRAX Praxis Precision Medicines	+0.90%	-3.96%	+14.82%	+26.71%	+676.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	37.68% Upside
BCRX BioCryst Pharmaceuticals	2.67	Moderate Buy	$20.60	107.66% Upside
KYMR Kymera Therapeutics	2.88	Moderate Buy	$128.70	8.10% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$585.95	65.78% Upside

Current Analyst Ratings Breakdown

Latest BCRX, ABVX, KYMR, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/31/2026	KYMR Kymera Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$135.00 ➝ $170.00
8/27/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/27/2026	KYMR Kymera Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$116.00 ➝ $151.00
8/24/2026	PRAX Praxis Precision Medicines	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	KYMR Kymera Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/7/2026	PRAX Praxis Precision Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$449.00 ➝ $462.00
8/7/2026	PRAX Praxis Precision Medicines	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$514.00
8/7/2026	PRAX Praxis Precision Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$323.00 ➝ $362.00
8/6/2026	KYMR Kymera Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$135.00

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
BCRX BioCryst Pharmaceuticals	$874.84M	2.90	$1.27 per share	7.83	($1.78) per share	-5.57
KYMR Kymera Therapeutics	$39.21M	252.46	N/A	N/A	$18.15 per share	6.56
PRAX Praxis Precision Medicines	$8.55M	1,154.16	N/A	N/A	$48.03 per share	7.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	13.78	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
KYMR Kymera Therapeutics	-$311.35M	-$3.24	N/A	N/A	N/A	-285.33%	-21.22%	-19.21%	11/3/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)

Latest BCRX, ABVX, KYMR, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/21/2026	Q2 2026	ABVX Abivax	-$0.9585	N/A	N/A	N/A	$0.78 million	N/A
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
8/5/2026	Q2 2026	KYMR Kymera Therapeutics	-$0.7126	-$0.62	+$0.0926	-$0.62	$32.78 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KYMR Kymera Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
KYMR Kymera Therapeutics	N/A	10.34	10.34
PRAX Praxis Precision Medicines	N/A	15.73	15.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
BCRX BioCryst Pharmaceuticals	85.88%
KYMR Kymera Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
BCRX BioCryst Pharmaceuticals	3.80%
KYMR Kymera Therapeutics	15.98%
PRAX Praxis Precision Medicines	3.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
BCRX BioCryst Pharmaceuticals	530	255.54 million	245.83 million	Optionable
KYMR Kymera Therapeutics	170	83.15 million	69.86 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable

BCRX, ABVX, KYMR, and PRAX Headlines

Recent News About These Companies

S&P 500 Futures Drop in Premarket Trading; Praxis Precision Meds, Science Applications Lead

August 31 at 8:03 AM | barrons.com

Bank of New York Mellon Corp Makes New $28.58 Million Investment in Praxis Precision Medicines, Inc. $PRAX

August 30 at 3:20 AM | marketbeat.com

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Buy" from Brokerages

August 27, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High - What's Next?

August 18, 2026 | marketbeat.com

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

August 17, 2026 | finance.yahoo.com

Praxis Precision Medicines (NASDAQ:PRAX) Trading 6.3% Higher - Still a Buy?

August 17, 2026 | marketbeat.com

9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB

August 16, 2026 | marketbeat.com

Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month High - Here's Why

August 12, 2026 | marketbeat.com

RBC Capital Reaffirms Their Buy Rating on Praxis Precision Medicines (PRAX)

August 11, 2026 | theglobeandmail.com

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

August 11, 2026 | zacks.com

Equities Analysts Offer Predictions for PRAX Q3 Earnings

August 11, 2026 | marketbeat.com

Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX

August 10, 2026 | marketbeat.com

Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest?

August 8, 2026 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Charles River Labs (CRL) and Senseonics Holdings (SENS)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), BioCryst (BCRX) and GH Research (GHRS)

August 8, 2026 | theglobeandmail.com

Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating

August 8, 2026 | marketbeat.com

Praxis signals two FDA decisions in ~six months, targets ~$10B ulixacaltamide peak sales while building a ~300-person field force

August 7, 2026 | seekingalpha.com

Praxis: Commercial Launch Could Smash Expectations (Video)

August 7, 2026 | seekingalpha.com

Praxis Precision Medicines, Inc. (PRAX) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX

August 7, 2026 | marketbeat.com

Praxis Precision Medicines Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, ABVX, KYMR, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

$113.67 +1.94 (+1.74%)

As of 09/1/2026 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.92 +0.22 (+2.27%)

As of 09/1/2026 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Kymera Therapeutics NASDAQ:KYMR

$119.05 +0.24 (+0.20%)

As of 09/1/2026 04:00 PM Eastern

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Praxis Precision Medicines NASDAQ:PRAX

$353.44 +3.14 (+0.90%)

As of 09/1/2026 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, ABVX, KYMR, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, ABVX, KYMR, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, ABVX, KYMR, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, ABVX, KYMR, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

BioCryst Pharmaceuticals NASDAQ:BCRX

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BCRX, ABVX, KYMR, and PRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BCRX, ABVX, KYMR, and PRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BCRX, ABVX, KYMR, and PRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX, ABVX, KYMR, and PRAX Company Descriptions

Abivax NASDAQ:ABVX

BioCryst Pharmaceuticals NASDAQ:BCRX

Kymera Therapeutics NASDAQ:KYMR

Praxis Precision Medicines NASDAQ:PRAX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools